Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

United Therapeutics CEO Martine Rothblatt executed pre-arranged stock option exercises and subsequent sales of common stock in late November 2025.

Summary

• Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (UTHR), reported transactions involving the exercise of stock options and subsequent sale of common stock.
• The transactions occurred on November 26, 2025, and November 28, 2025.
• These transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan, which was entered into on May 2, 2025.
• On November 26, 2025, 4,000 shares were acquired through option exercise at $120.26 per share, and 4,000 shares were sold at weighted average prices ranging from $484.4498 to $487.1.
• On November 28, 2025, an additional 4,000 shares were acquired through option exercise at $120.26 per share, and 4,000 shares were sold at weighted average prices ranging from $485.7125 to $490.25.
• The 10b5-1 plan covers a tranche of 294,000 stock options that expire on March 15, 2026, and is set to continue until December 31, 2025, or until the exhaustion of this tranche.
• Following these transactions, the reporting person directly holds 130 shares of common stock and indirectly holds 166 shares through a spouse, and 644,193 shares through various family trusts.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic trading, indicating a planned liquidity event rather than a reaction to adverse company-specific news.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which demonstrates a planned approach to managing equity holdings and helps mitigate concerns about opportunistic insider trading.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by investors as it reduces the direct equity stake of a key executive.

Future Outlook

The pre-arranged 10b5-1 trading plan is scheduled to continue until December 31, 2025, or until the tranche of 294,000 stock options expiring March 15, 2026, is fully exhausted, indicating potential for further planned transactions.

Management Comments

• "This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025."

Industry Context

Form 4 filings are a standard regulatory requirement for insiders of publicly traded companies. The use of a Rule 10b5-1 trading plan is a common and accepted practice among executives to manage their personal equity holdings for diversification and liquidity purposes, while adhering to insider trading regulations.

Comparison to Industry Standards

• The utilization of a Rule 10b5-1 plan by a corporate insider is considered a best practice within the industry, providing an affirmative defense against potential insider trading allegations.
• Many executives at comparable pharmaceutical and biotechnology companies routinely establish and execute such plans to manage their equity compensation and personal financial planning.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership of common stock is reported through various family trusts where the reporting person, their spouse, and/or immediate family members are beneficiaries or trustees.

Stakeholder Impact

• Shareholders may observe a reduction in the direct beneficial ownership of common stock by the CEO, though the pre-planned nature of the transactions under a 10b5-1 plan typically lessens negative interpretations.
• The transparency provided by the 10b5-1 plan can reassure stakeholders that executive stock transactions are conducted ethically and in compliance with regulations.

Next Steps

• Continuation of the pre-arranged 10b5-1 trading plan until December 31, 2025, or until the specified tranche of stock options is exhausted.

Key Dates

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Share Sale, CEO, Director